USE OF COHERENT RAMAN TECHNIQUES FOR MEDICAL DIAGNOSTIC AND THERAPEUTIC PURPOSES, AND CALIBRATION TECHNIQUES FOR SAME

• US 20080117416A1
• Filed: 10/29/2007
• Published: 05/22/2008
• Est. Priority Date: 10/27/2006
• Status: Abandoned Application

• Current Assignee: Aretais Incorporated
• Original Assignee: Aretais Incorporated
• Inventors: Anquetil, Patrick A., Lafontaine, Serge, Somaroo, Shyamal, Hunter, Ian W., Tseng, Ching-Hua
• Application Number:
  US11/927,557
• Publication Number:
  US 20080117416A1
• Time in Patent Office: Days
• US Class Current: 356/301
• CPC Class Codes: A61B 5/0059 using light, e.g. diagnosis by transillumination, diascopy, fluorescence A61B5/0093, A61B5/1455, A61B5/02416 and A61B5/0261 take precedence
• CPC Class Codes: A61B 5/0066 Optical coherence imaging
• CPC Class Codes: A61B 5/0075 by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy A61B5/0071 takes precedence
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/412 Detecting or monitoring sepsis
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61B 5/444 Evaluating skin marks, e.g. mole, nevi, tumour, scar
• CPC Class Codes: A61B 5/445 Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
• CPC Class Codes: G01N 2021/653 Coherent methods [CARS]
• CPC Class Codes: G01N 21/276 with alternation of sample and standard in optical path
• CPC Class Codes: G01N 21/65 Raman scattering

Abstract

System and methods are provided to perform non-invasive, real-time, continuous molecular detection and quantification of molecular species in a sample or animal subject using Raman spectroscopy. Such systems and methods may be applied to identify and quantify molecular species found in the body, which may be useful for prenatal diagnosis, detecting deep skin infections, performing cerebral spinal fluid assessment, measuring arterial blood gases, blood glucose, cardiac biomarkers, creatinine flow rates. The non-invasive, quantification of such molecular species continuously in real time enables a significantly more attractive course of therapy than existing protocols.

Claims

1. A method to measure the concentration of a target analyte in an animal subject using Raman spectroscopy comprising:

measuring ex vivo a concentration of a target analyte in an animal subject;

illuminating a portion of said animal subject with light so as to cause radiation to scatter from a reference analyte and said target analyte in said sample;

detecting said scattered radiation from said reference analyte and from said target analyte;

measuring an electrical signal corresponding to an amount of detected radiation from said reference analyte;

measuring an electrical signal corresponding to an amount of detected radiation from said target analyte;

calculating an attenuation factor based on said signal from said reference analyte;

correcting the signal of said target analyte based on the attenuation factor; and

determining an absolute concentration of said target analyte in said animal subject from said corrected signal.

2. The method of claim 1, wherein said Raman spectroscopy is coherent.

3. The method of claim 1, further comprising imaging said illuminated portion of said animal subject to help locate where said reference analyte and target analyte may be present in said animal subject.

4. The method of claim 1, wherein illuminating said portion of said animal subject with light includes focusing said light to a focal plane in said portion of said animal subject;

and wherein detecting said scattered radiation from said reference analyte includes collecting scattered radiation from said focal plane.

5. The method of claim 4, wherein said focusing is to a point or to a line at said focal plane of said portion of said animal subject.

6. The method of claim 4, wherein illuminating said portion of said animal subject with light includes scanning said light across said portion of said animal subject.

12. The method of claim 1, wherein said reference analyte naturally exists in said animal subject or does not naturally exist in said animal subject.

13. The method of claim 1, wherein said detection of said scattered radiation is non-invasive.

14. The method of claim 1, wherein said detection is partially-invasive.

15. The method of claim 14, wherein said detection is performed through a subcutaneous probe or performed on a biopsy.

16. The method of claim 1, wherein said portion of said animal subject is skin or a wound culture.

17. The method of claim 1, wherein said portion of said animal subject is at least one member selected from the group consisting of tissue, secretion products, excretion products, exogenous material, aminiotic fluid, bile, blood, blood plasma, cerumen, cowper'"'"'s fluid, chyle, chyme, lymph, menses, breast milk, mucus, pleural fluid, pus, sebum, serum, urine, saliva, semen, sweat, tears, stool, ocular aqueous humor, pulmonary exhalate, phlegm, gastrointestinal gavage, pulmonary gavage, and skin, stem cells, bone marrow, cerebral spinal fluid, and transplant tissue.

18. The method of claim 1, wherein said method is operable to identify in said portion of said animal subject at least one member selected from the group consisting of a chromosomal composition, metabolite, blood gas, biomarker, bacteria, virus, infectious disease biomarker in a fetus, meningitis, subarachnoid hemorrhage, hydrocephalus, benign intracranial hypertension, cancer, inflammation, Multiple Sclerosis/Guillian-Barre, neurosyphillis, Down syndrome, Tay-Sachs, cystic fibrosis, genetic disease arising from chromosomal deletion, duplication, translocation, inversion, or ring formation, cholesterol, triglycerides, C-reactive protein, bilirubin, alkaline phosphatase, alanine aminotransferase, AST/GOT, TSH, creatinine, albumin, CK-MB, myoglobin, troponin I, B-type Natriuretic Peptide (BNP), cancer specific markers, cancer antigens, prostate specific antigen (PSA), cell count, cell morphology, pharmaceutical composition, or a therapeutic drug.

19. The method of claim 1, wherein said reference analyte is Hb1Ac.

21. The method of claim 17, wherein urine is illuminated under flow conditions.

22. The method of claim 21, wherein said target analyte is creatinine.

7. A system to measure the concentration of a target analyte using Raman spectroscopy comprising:

a source of illumination that can cause radiation to scatter from a reference analyte and a target analyte in a sample;

a detector to measure said scattered radiation from said reference analyte and from said target analyte; and

a processor to calculate an attenuation factor based on said measure of scattered radiation from said reference analyte, to correct said measure of scattered radiation from said target analyte based on said attenuation factor; and

to determine an absolute concentration of said target analyte in said animal subject from said corrected measure of said target analyte.

8. The system of claim 7, wherein said source of illumination is a coherent Raman laser system.

9. The system of claim 7, further comprising an imaging system to help locate a suitable location in said sample to illuminate said reference analyte and said target analyte.

10. The system of claim 7, further comprising scanning optics to scan said light across a portion of said sample.

11. The system of claim 7, further comprising an endoscope that is optically coupled to said source of illumination, and said detector.

20. The system of claim 7, wherein said source of illumination is capable of illuminating a sample of blood and detecting scattered radiation from said sample to monitor a blood glucose level in real time.